Niagen Bioscience (NAGE) Q4 2020 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2020 earnings summary
19 Nov, 2026Executive summary
Q4 2020 net sales rose 18% YoY to $15.4M; Tru Niagen sales rose 21% YoY to $12.3M, with continued sequential growth.
FY 2020 net sales increased 28% to $59.3M; adjusted EBITDA excluding legal expense improved to a $1.0M loss from an $8.8M loss in 2019.
Ended 2020 with $16.7M in cash and raised $25M through a common-stock investment in February 2021.
Financial highlights
Q4 net loss was $6.1M, or $0.10/share, versus a $8.9M loss, or $0.15/share, in Q4 2019; operating loss narrowed to $6.1M from $8.9M.
Q4 net sales were $15.4M, up 18% YoY and 9% QoQ; FY sales were $59.3M, up 28% YoY.
FY 2020 net loss was $19.9M versus $32.1M in 2019; cash used in operations was $10.6M versus $20.4M.
Outlook and guidance
FY 2021 outlook calls for continued steady revenue growth, supported by global e-commerce and existing and new strategic partnerships.
Gross margin expected to be slightly above 60%; selling and marketing and R&D expected to remain roughly flat as a share of sales.
Adjusted EBITDA excluding legal expense expected to improve modestly as higher sales and gross margins are largely offset by investments to scale the business.
Planned investments include brand awareness, R&D pipeline and new NAD precursor development, key personnel, and infrastructure.
Latest events from Niagen Bioscience
- TRU NIAGEN drove 49% FY sales growth, while losses widened and break-even remained a 2019/20 target.NAGE
Q4 2018 - TRU NIAGEN drove 47% FY sales growth as margins improved and global expansion continued.NAGE
Q4 2019 - Consumer expansion and rare-disease development anchor a four-part growth strategy.NAGE
A.G.P. Virtual Consumer Showcase - A profitable NAD+ platform is funding expansion into IVs, skincare, and therapeutics.NAGE
Corporate presentation - Q3 sales fell 20% as investment and new launches targeted future growth.NAGE
Q3 2026 - Rare-disease drug ambitions extend a profitable NAD platform into new channels.NAGE
LD Micro 20th Annual Main Event Conference - Strong growth, innovation, and a leading NAD drug pipeline position the company for future success.NAGE
17th Annual Midwest IDEAS Conference - Strong NAD+ supplement sales, new skincare launches, and robust cash flow support biotech growth.NAGE
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 delivered $29.8M sales, $1M net income, and major telehealth and pharma launches.NAGE
Q2 2026